Table 3.

Statistically significant differences in clinical characteristics and laboratory findings between patients who survived and died

Clinical characteristics and laboratory findings, number of patients	Patients who died	Patients who survived	P-value
Age, mean ± SD, 442 patients	49.09±14.588	39.43±19.412	0.006
Duration from zinc phosphide exposure to hospital visit in hours, median (min–max), 442 patients	3 (0.33–24)	1 (0.083–120)	0.001
Tachycardia at presentation (>100 beats/minute), % of 411 patients	33.3	13.1	0.015
Low systolic blood pressure at presentation (<90 mmHg), % of 410 patients	30.0	1.6	<0.001
Low diastolic blood pressure at presentation (<60 mmHg), % of 409 patients	33.3	3.4	<0.001
Tachypnea at presentation (>20 breaths/minute), % of 370 patients	38.5	14.5	0.004
Hypernatremia at presentation (>145 mmol/L), % of 328 patients	25.0	3.9	0.001
Hyperkalemia at presentation (>5.5 mmol/L), % of 330 patients	8.3	0.7	0.014
Acidosis (by electrolyte analysis) at presentation, % of 324 patients	60.9	8.0	<0.001
Acute kidney injury, % of 309 patients	50.0	6.3	<0.001
Hypoglycemia, % of 92 patients	40.0	3.7	<0.001
Endotracheal tube intubation, % of 442 patients	68.8	2.2	<0.001
Inotropic agent administration, % of 442 patients	94.7	5.3	<0.001

Abbreviations: SD, standard deviation; min, minimum; max, maximum.